-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HBF-0259
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/957011-15-3.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 957011-15-3 |
| Description | HBF-0259 is a potent and selective hepatitis B virus (HBV) surface antigen (HBsAg) secretion inhibitor, with an EC50 of 1.5 μM in HepG2.2.15 cells. It has no effect on HBV DNA synthesis. |
Product Information
| Synonyms | Tetrazolo[1,5-a]pyrimidine, 7-(2-chloro-6-fluorophenyl)-5-(4-chlorophenyl)-1,5,6,7-tetrahydro-; 7-(2-Chloro-6-fluorophenyl)-5-(4-chlorophenyl)-1,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine |
| IUPAC Name | 7-(2-chloro-6-fluorophenyl)-5-(4-chlorophenyl)-4,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine |
| Molecular Weight | 364.20 |
| Molecular Formula | C16H12Cl2FN5 |
| Canonical SMILES | C1C(NC2=NN=NN2C1C3=C(C=CC=C3Cl)F)C4=CC=C(C=C4)Cl |
| InChI | InChI=1S/C16H12Cl2FN5/c17-10-6-4-9(5-7-10)13-8-14(24-16(20-13)21-22-23-24)15-11(18)2-1-3-12(15)19/h1-7,13-14H,8H2,(H,20,21,23) |
| InChIKey | BRBZPYDLUUWBCD-UHFFFAOYSA-N |
| Boiling Point | 429.6±55.0°C (Predicted) |
| Purity | ≥95% |
| Density | 1.60±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Storage | Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| Complexity | 437 |
| Exact Mass | 363.0453790 |
| In Vitro | HBF-0259 (0.0158-50.0 μM) inhibits the HBsAg secretion (EC50=1.5 μM) in HepDE19 cells, with an CC50 of >50 μM. HBF-0259 (2-8 μM) significantly reduces the abundance of both L and M in the supernatants of HepG2.2.15 cells. |
| In Vivo | HBF-0259 (0.0158-50.0 μM) inhibits the HBsAg secretion (EC50=1.5 μM) in HepDE19 cells, with an CC50 of >50 μM. |
| Target | HBV |
| XLogP3-AA | 4.5 |
